Compare NATH & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATH | IVVD |
|---|---|---|
| Founded | 1916 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.8M | 437.1M |
| IPO Year | 1996 | 2021 |
| Metric | NATH | IVVD |
|---|---|---|
| Price | $100.26 | $1.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 38.2K | ★ 1.6M |
| Earning Date | 05-22-2026 | 06-08-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | 22.29 | ★ 79.02 |
| EPS | ★ 4.17 | N/A |
| Revenue | ★ $104,201,000.00 | $53,426,000.00 |
| Revenue This Year | N/A | $143.48 |
| Revenue Next Year | N/A | $25.40 |
| P/E Ratio | $24.07 | ★ N/A |
| Revenue Growth | 7.81 | ★ 110.47 |
| 52 Week Low | $88.00 | $0.46 |
| 52 Week High | $118.32 | $3.07 |
| Indicator | NATH | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 50.50 |
| Support Level | $100.25 | $1.41 |
| Resistance Level | $101.86 | $2.01 |
| Average True Range (ATR) | 0.43 | 0.11 |
| MACD | -0.19 | 0.04 |
| Stochastic Oscillator | 16.45 | 56.18 |
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.